Seres Therapeutics (MCRB) Insider Trading & Ownership $0.92 -0.01 (-0.59%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Seres Therapeutics (NASDAQ:MCRB) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage5.10%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)5Amount OfInsider Selling(Last 12 Months)$68,758.79 Get MCRB Insider Trade Alerts Want to know when executives and insiders are buying or selling Seres Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address MCRB Insider Buying and Selling by Quarter Ad Paradigm Press Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000!Click here now for the urgent details. Seres Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails11/18/2024Eric D ShaffCEOSell2,505$0.54$1,352.70 11/18/2024Moltke Lisa VonInsiderSell977$0.54$527.58 11/18/2024Thomas DesrosierEVPSell878$0.54$474.12 10/28/2024Eric D ShaffCEOSell8,748$0.69$6,036.12 10/28/2024Moltke Lisa VonInsiderSell4,334$0.69$2,990.46 10/28/2024Thomas DesrosierEVPSell4,259$0.69$2,938.71 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 8/16/2024Eric D ShaffCEOSell2,518$0.84$2,115.12 8/16/2024Moltke Lisa VonInsiderSell973$0.84$817.32 8/16/2024Thomas DesrosierEVPSell873$0.84$733.32 8/5/2024Teresa L YoungInsiderSell24,480$1.08$26,438.40 5/15/2024Eric D ShaffCEOSell2,435$0.94$2,288.90 5/15/2024Moltke Lisa VonInsiderSell939$0.94$882.66 5/15/2024Thomas DesrosierEVPSell843$0.94$792.42 2/16/2024David ArkowitzCFOSell3,939$1.08$4,254.12 2/16/2024Eric D ShaffCEOSell11,549$1.08$12,472.92 2/16/2024Teresa L YoungInsiderSell3,374$1.08$3,643.92 (Data available from 1/1/2013 forward) MCRB Insider Trading Activity - Frequently Asked Questions Who is on Seres Therapeutics's Insider Roster? The list of insiders at Seres Therapeutics includes David Arkowitz, David S Ege, Eric D Shaff, Health Ltp Fund Ge Nutritional, Moltke Lisa Von, Paula Cloghessy, Teresa L Young, and Thomas Desrosier. Learn more on insiders at MCRB. What percentage of Seres Therapeutics stock is owned by insiders? 5.10% of Seres Therapeutics stock is owned by insiders. Learn more on MCRB's insider holdings. Which Seres Therapeutics insiders have been selling company stock? The following insiders have sold MCRB shares in the last 24 months: David Arkowitz ($9,743.22), David S Ege ($36,527.22), Eric D Shaff ($35,810.96), Moltke Lisa Von ($5,218.02), Paula Cloghessy ($3,920.40), Teresa L Young ($30,082.32), and Thomas Desrosier ($10,549.17). How much insider selling is happening at Seres Therapeutics? Insiders have sold a total of 100,340 Seres Therapeutics shares in the last 24 months for a total of $131,851.31 sold. Seres Therapeutics Key ExecutivesMr. Eric D. Shaff M.B.A. (Age 48)President, CEO & Director Compensation: $1.02M3 recent tradesDr. Lisa von Moltke M.D. (Age 65)Executive VP & Chief Medical Officer Compensation: $725.15kDr. Teresa L. Young Ph.D. (Age 57)R.Ph., Executive VP and Chief Commercial & Strategy Officer Compensation: $606.33kMs. Marella Thorell (Age 57)Executive VP & CFO Dr. David S. Ege Ph.D. (Age 49)Executive VP & Chief Technology Officer Compensation: $142.71kDr. Matthew R. Henn Ph.D. (Age 49)Executive VP & Chief Scientific Officer Compensation: $643.83kMr. Carlo Tanzi Ph.D.Investor Relations OfficerMr. Thomas J. DesRosier Esq. (Age 69)J.D., Chief Legal Officer, Executive VP & Secretary Compensation: $719.55kMs. Caroline HoldaAssistant General Counsel More Insider Trading Tools from MarketBeat Related Companies ORIC Pharmaceuticals Insider Ownership Terns Pharmaceuticals Insider Ownership Tourmaline Bio Insider Ownership Phathom Pharmaceuticals Insider Ownership ProKidney Insider Ownership Astria Therapeutics Insider Ownership Ginkgo Bioworks Insider Ownership Annexon Insider Ownership Humacyte Insider Ownership AnaptysBio Insider Ownership Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles AppLovin Insiders Sell Shares: Stock Price Indicated Higher Are 2024’s Top Insider Buys a Good Bet for 2025? Bargains Galore? 3 Stocks With Insider Buying in the MillionsInsiders Keep Buying These Stocks: 2 to Buy, 1 to AvoidZeta Global Holdings Insiders Buy Stock After Short-Report This page (NASDAQ:MCRB) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seres Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seres Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
